Nivolumab Plus Ipilimumab-Based Treatment in Japanese Patients with Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 < 1

Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1